Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
THE BTK INHIBITOR PCI-32765 IS HIGHLY ACTIVE AND WELL TOLERATED IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY B CELL MALIGNANCIES: FINAL RESULTS FROM A PHASE I STUDY Advani, R. H., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B. W., Kolibaba, K. S., Furman, R. R., Buggy, J. J., Loury, D. J., Hedrick, E., Izumi, R., Hamdy, A. M., Fowler, N. H. OXFORD UNIV PRESS. 2011: 135
View details for Web of Science ID 000291996300165